Sodium tanshinone IIA sulfonate protects cardiomyocytes against oxidative stress-mediated apoptosis through inhibiting JNK activation

被引:182
作者
Yang, Ruifang [1 ]
Liu, Aijun [1 ]
Ma, Xiujuan [1 ]
Li, Lin [1 ]
Su, Dingfeng [1 ]
Liu, Jianguo [1 ]
机构
[1] Second Mil Med Univ, Sch Pharm, Dept Pharmacol, Shanghai 200433, Peoples R China
关键词
sodium tanshinone IIA sulfonate; myocardial infarction; oxidative stress; apoptosis; JNK;
D O I
10.1097/FJC.0b013e3181671439
中图分类号
R5 [内科学];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
Sodium tanshinone IIA sulfonate (STS) is a water-soluble derivative of tanshinone IIA, a well-known Chinese medicine for treating cardiovascular disorders. Cardiomyocyte apoptosis plays a major role in the development of cardiovascular diseases. The present study was designed to investigate the effects of STS on cardiomyocyte apoptosis induced by in vivo acute myocardial infarction (MI) in adult rats and by in vitro H2O2-treated neonatal rat ventricular myocytes. In MI rats, STS significantly reduced the infarct sizes, the blood lactate dehydrogenase (LDH) level, and the number of apoptotic cardiomyocytes in the infarcted hearts. In the in vitro study, STS reversed the decreased effect of cell viability induced by H2O2. In addition, STS also markedly inhibited H2O2-induced cardiomyocyte apoptosis. C-Jun N-terminal kinases/stress-activated protein kinases (JNKs/SAPKs) and p38 MAPK are classic oxidative stress activated protein kinases. Our further mechanistic study revealed that increased JNK phosphorylation stimulated by H2O2 was abolished by STS treatment. In conclusion, inhibition of JNK activation plays a significant role in cardioprotective effects of STS.
引用
收藏
页码:396 / 401
页数:6
相关论文
共 44 条
[1]
In vivo hyperoxic preconditioning prevents myocardial infarction by expressing Bcl-2 [J].
Choi, H ;
Kim, SH ;
Chun, YS ;
Cho, YS ;
Park, JW ;
Kim, MS .
EXPERIMENTAL BIOLOGY AND MEDICINE, 2006, 231 (04) :463-472
[2]
Inhibition of Cap-initiation complexes linked to a novel mechanism of eIF4G depletion in acute myocardial ischemia [J].
Connolly, E. P. ;
Thuillier, V. ;
Rouy, D. ;
tard, G. Boue ;
Schneider, R. J. .
CELL DEATH AND DIFFERENTIATION, 2006, 13 (09) :1586-1594
[3]
Duplain H, 2006, ADV EXP MED BIOL, V588, P157
[4]
Metabolic derangement in ischemic heart disease and its therapeutic control [J].
Ferrari, R ;
Pepi, P ;
Ferrari, F ;
Nesta, F ;
Benigno, M ;
Visioli, O .
AMERICAN JOURNAL OF CARDIOLOGY, 1998, 82 (5A) :2K-13K
[5]
cGMP-dependent protein kinase type I inhibits TAB1-p38 mitogen-activated protein kinase apoptosis signaling in cardiac myocytes [J].
Fiedler, Beate ;
Feil, Robert ;
Hofmann, Franz ;
Willenbockel, Christian ;
Drexler, Helmut ;
Smolenski, Albert ;
Lohmann, Suzanne M. ;
Wollert, Kai C. .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2006, 281 (43) :32831-32840
[6]
Gao Y G, 1979, Yao Xue Xue Bao, V14, P75
[7]
Garlid KD, 1997, CIRC RES, V81, P1072
[8]
Oxidative stress and apoptosis in heart failure progression [J].
Hare, JM .
CIRCULATION RESEARCH, 2001, 89 (03) :198-200
[9]
Apoptosis - Basic mechanisms and implications for cardiovascular disease [J].
Haunstetter, A ;
Izumo, S .
CIRCULATION RESEARCH, 1998, 82 (11) :1111-1129
[10]
HE WA, 2005, CHINESE J PRACTICAL, V18, P1890